TIDMSTX TIDMSTXW
RNS Number : 3565J
Shield Therapeutics PLC
28 June 2017
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE
OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION
WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF
THIS ANNOUNCEMENT.
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Admission of New Ordinary Shares
London, UK, 28 June 2017: Shield Therapeutics (LSE: STX), a
specialty pharmaceutical company focused on secondary care, is
pleased to announce that 7,967,205 new ordinary shares in the
Company have today been admitted to trading on the AIM market of
the London Stock Exchange pursuant to the coordinated Warrant
Exercise, Placing and Subscription (constituting the Fundraise) as
announced on 15 June 2017.
The Company does not hold any shares in treasury. Therefore,
there are now 116,102,621 ordinary shares in issue and 4,796,122
warrants still outstanding. These warrants are due to expire on 30
June 2017 (unless exercised prior to such date). The figures shown
above may be used by shareholders as the denominators for the
calculations by which they may determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure and Transparency Rules.
In addition to the warrants exercised as part of the Fundraise,
as at close of business on 27 June 2017, the Company's registrar
had received further warrant exercises in respect of 292,230 new
ordinary shares, for aggregate gross subscription proceeds of
GBP438,345. Admission of these additional ordinary shares will take
place in accordance with the terms of the warrant instrument
following expiry of the remaining warrants on 30 June 2017, along
with any other new ordinary shares to be issued pursuant to any
further warrant exercises between now and warrant expiry. The
warrants being exercised are included in the figure of 4,796,122
warrants referred to above as being still outstanding.
Notes
All defined terms used in this announcement shall have the same
meaning as defined in the Company's announcement published on 15
June 2017.
Enquiries
Shield Therapeutics plc +44 (0)20 7186 8500
Carl Sterritt, Chief Executive Officer
Joanne Estell, Chief Financial Officer
Karl Keegan, Director Corporate Development
Nominated Adviser, Joint Bookrunner and Joint Broker +44 (0)20 3100 2222
Liberum Capital Limited
Christopher Britton
Steve Pearce
Jonathan Wilkes-Green
Joint Bookrunner and Joint Broker +44 (0)20 7418 8900
Peel Hunt LLP
James Steel
Alastair Rae
Oliver Jackson
Financial PR Advisor +44 (0) 203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott
Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals which address areas of unmet
medical need. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru(R), for the treatment of iron deficiency anaemia
(IDA) in adult patients with inflammatory bowel disease (IBD) which
has exclusive IP rights until the mid-2030's. In addition, the
Group is developing PT20, a late-stage pharmaceutical for the
treatment of systemic phosphate accumulation (hyperphosphatemia).
Shield Therapeutics, headquartered in London, is listed on LSE's
AIM under the ticker STX. For more information please visit
www.shieldtx.com
IMPORTANT NOTICE
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS FOR
INFORMATION PURPOSES ONLY, IS NOT INTENDED TO AND DOES NOT
CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO PURCHASE OR
SUBSCRIBE FOR, UNDERWRITE, SELL OR ISSUE OR THE SOLICITATION OF AN
OFFER TO PURCHASE OR SUBSCRIBE, SELL, ACQUIRE, DISPOSE OF THE
COMPANY'S ORDINARY SHARES OR ANY OTHER SECURITY IN THE UNITED
STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE
UNITED STATES AND THE DISTRICT OF COLUMBIA, COLLECTIVELY THE
"UNITED STATES"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR IN
ANY JURISDICTION IN WHICH, OR TO ANY PERSONS TO WHOM, SUCH
OFFERING, SOLICITATION OR SALE WOULD BE UNLAWFUL.
The Company's ordinary shares have not been and will not be
registered under the United States Securities Act of 1933, as
amended (the "Securities Act") or under the securities laws of any
state or other jurisdiction of the United States, and may not be
offered, sold or transferred, directly or indirectly, in or into
the United States except pursuant to an exemption from, or in a
transaction not subject to, the registration requirements of the
Securities Act and in compliance with any applicable securities
laws of any state or other jurisdiction of the United States. There
will be no public offering of the Company's ordinary shares in the
United States, the United Kingdom or elsewhere.
The relevant clearances have not been, and nor will they be,
obtained from the securities commission of any province or
territory of Canada; no prospectus has been lodged with, or
registered by, the Australian Securities and Investments Commission
or the Japanese Ministry of Finance; and the Company's ordinary
shares have not been, and nor will they be, registered under or
offered in compliance with the securities laws of any state,
province or territory of Canada, Australia, Japan or South Africa.
Accordingly, the Company's ordinary shares may not (unless an
exemption under the relevant securities laws is applicable) be
offered, sold, resold or delivered, directly or indirectly, in or
into Canada, Australia, Japan or South Africa or any other
jurisdiction outside the United Kingdom or to, or for the account
or benefit of any national, resident or citizen of Australia, Japan
or South Africa or to any investor located or resident in
Canada.
Each of Liberum and Peel Hunt (together, the "Joint
Bookrunners") is authorised and regulated in the United Kingdom by
the Financial Conduct Authority and is acting exclusively for the
Company in connection with the Placing and no one else and will not
be responsible to anyone other than the Company for providing the
protections afforded to its clients nor for providing advice to any
other person in relation to the Placing and/or any other matter
referred to in this announcement.
This announcement is being issued by and is the sole
responsibility of the Company. No representation or warranty,
express or implied, is or will be made as to, or in relation to,
and no responsibility or liability is or will be accepted by the
Joint Bookrunners (apart from the responsibilities or liabilities
that may be imposed by the FSMA, as amended, or the regulatory
regime established thereunder) or any of their respective
affiliates or any of their respective directors, officers,
employees, advisers, representatives or shareholders (collectively,
"Representatives") for the contents of this announcement, or any
other written or oral information made available to or publicly
available to any interested party or its advisers, or any other
statement made or purported to be made by or on behalf of the Joint
Bookrunners or any of their respective affiliates or by any of
their respective Representatives in connection with the Company,
the Placing Shares or the Placing and any responsibility and
liability whether arising in tort, contract or otherwise therefore
is expressly disclaimed. The Joint Bookrunners and each of their
respective affiliates and each of their respective Representatives
accordingly disclaim all and any liability, whether arising in
tort, contract or otherwise (save as referred to above) in respect
of any statements or other information contained in this
announcement and no representation or warranty, express or implied,
is made by the Joint Bookrunners or any of their respective
affiliates or any of their respective Representatives as to the
accuracy, fairness, verification, completeness or sufficiency of
the information contained in this announcement and nothing in this
announcement is, or shall be relied upon as, a promise or
representation in this respect, whether as to the past or
future.
The new ordinary shares to be issued pursuant to the Warrant
Exercise, Placing and Subscription will not be admitted to trading
on any stock exchange other than the AIM market operated by the
London Stock Exchange.
Neither the content of the Company's website nor any website
accessible by hyperlinks on the Company's website is incorporated
in, or forms part of, this announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUBUARBUANUUR
(END) Dow Jones Newswires
June 28, 2017 03:00 ET (07:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jul 2023 to Jul 2024